Posted by Michael Wonder on 20 May 2022
Mirati Therapeutics submits marketing authorisation application to the European Medicines Agency for investigational adagrasib as a treatment for previously treated KRASG12C mutated non-small-cell lung cancer
19 May 2022 - Submission follows the U.S. FDA acceptance of the adagrasib new drug application for the same indication
Mirati Therapeutics today announced that it has submitted a marketing authorisation application to the EMA for adagrasib for the treatment of patients with non-small cell lung cancer harbouring the KRASG12C mutation who have received at least one prior systemic therapy.
